Vuity vs Syfovre
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vuity | US Syfovre | |
|---|---|---|
| Generic name | pilocarpine ophthalmic | pegcetacoplan |
| Drug class | Cholinergic Muscarinic Agonist (Eye Drop) | Complement C3 Inhibitor |
| Treats | Age-related blurry near vision (presbyopia) | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Apellis Pharmaceuticals |
| Year approved | 2021 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $70M | — |
| Common side effects | Headache, Eye redness, Trouble with night vision, Eye pain | Eye discomfort, Floaters, Bleeding in the eye, Increased eye pressure |
Frequently asked questions
Is Vuity or Syfovre better?
Neither is universally "better." Vuity (pilocarpine ophthalmic) and Syfovre (pegcetacoplan) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vuity and Syfovre?
Vuity is a Cholinergic Muscarinic Agonist (Eye Drop) made by AbbVie (Allergan), while Syfovre is a Complement C3 Inhibitor made by Apellis Pharmaceuticals. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vuity has the larger estimated TV advertising budget of the two.